Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study aims to estimate the effect of the practice of a short-term partial fasting compared to a usual alimentation on nausea and vomiting within 5 days after the start of a chemotherapy session on 2 successive chemotherapy courses (4 sessions of chemotherapy) in patients starting treatment with highly emetogenic chemotherapy (ABVD or AVD protocol).
Patients in fasting arm will practice partial fasting during 3 days (D-1, D1 (D day of chemotherapy) and D2) following a food guide during 4 chemotherapy sessions. Patients in usual alimentation arm will continue to take food as usual practice.
In each arm, patients will be interviewed at each chemotherapy sessions about nausea and vomiting (number and intensity of nausea and vomiting, treatments taken). Denutrition, quality of life improvement, compliance to partial fasting, treatment response will be evaluate too.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| intervention group | Experimental | therapeutic fasting |
|
| control group | No Intervention | usual alimentation |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| therapeutic fasting | Other | fasting limited to daily 250 kcal during 3 days (day before chemotherapy, the D day of the chemotherapy and the day after chemotherapy) |
|
| Measure | Description | Time Frame |
|---|---|---|
| nausea and vomiting evaluation and quantification | Anti-emetic tool from MASCC (Multinational Association of Supportive Care in Cancer) | Day 1 (first day of the chemotherapy cycle), |
| nausea and vomiting evaluation and quantification | Anti-emetic tool from MASCC (Multinational Association of Supportive Care in Cancer) | day 2 of the chemotherapy cycle |
| nausea and vomiting evaluation and quantification | Anti-emetic tool from MASCC (Multinational Association of Supportive Care in Cancer) | day 3 of the chemotherapy cycle |
| nausea and vomiting evaluation and quantification | Anti-emetic tool from MASCC (Multinational Association of Supportive Care in Cancer) | day 4 of the chemotherapy cycle |
| nausea and vomiting evaluation and quantification | Anti-emetic tool from MASCC (Multinational Association of Supportive Care in Cancer) | day 5 of the chemotherapy cycle |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Mélanie BEGORRE | Contact | +262 (0)262 90 78 85 | melanie.begorre@chu-reunion.fr |
| Name | Affiliation | Role |
|---|---|---|
| Marie-Elora MUSSARD | CHU de La Réunion | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHU de la Réunion | Recruiting | Saint-Pierre | 97410 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D014839 | Vomiting |
| ID | Term |
|---|---|
| D012817 | Signs and Symptoms, Digestive |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided